- Studying SARS-CoV‑2 collectively -
The new SARS-CoV‑2 is spreading rapidly. Mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society we want to better understand the implications of the new virus on patients by systematically documenting patient data.
The SARS-CoV‑2 pandemic is a major challenge for medical professionals worldwide, with a daily increase of new infections.
Currently, there is a gap of knowledge regarding the best possible clinical management of the infection as well as the prediction and prevention of severe outcomes.
We initiated the Lean European Open Survey on SARS-CoV‑2 (LEOSS) project, a prospective European multi-center cohort study, to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV‑2.
Our goal is to establish a quick and simple register that allows anonymous documentation of patients. The study will allow retrospective inclusion of patients treated before the initiation of the study.
The obtained data can be used to identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV‑2. The Data Use and Access Policy developed within the LEOSS community allows a dynamic and fast scientific use of the data while maintaining high scientific quality as well as responsible public communication
The eCRF ensures the documentation of the following items. It is regularly revised and adjusted in cooperation with medical societies and partners according to their expertise and updated information.
We are part of the MDM portal (Medical data model – medical-data-models.org). It’s a European meta-data register for the creation, analysis, approval, and reuse of medical forms. In order to enhance transparency, reusability, and comparability of different studies, the LEOSS data model with all data points being encoded via UMLS (Unified Medical Language System is available online now. You can find it here.